These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25926720)

  • 1. Roles of Ca(2+)/calmodulin-dependent protein kinase II in subcellular expression of striatal N-methyl-D-aspartate receptors in l-3, 4-dihydroxyphenylalanine-induced dyskinetic rats.
    Gan J; Qi C; Liu Z
    Drug Des Devel Ther; 2015; 9():2119-28. PubMed ID: 25926720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of CaMKIIa-GluN2B interaction in levodopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's rats.
    Wang XS; Zhang ZR; Zhang XR; Chen SY; Shao B; Xie CL
    Biomed Pharmacother; 2018 Nov; 107():769-776. PubMed ID: 30142538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in subcellular distribution and phosphorylation of GluR1 in lesioned striatum of 6-hydroxydopamine-lesioned and l-dopa-treated rats.
    Ba M; Kong M; Yang H; Ma G; Lu G; Chen S; Liu Z
    Neurochem Res; 2006 Nov; 31(11):1337-47. PubMed ID: 17053970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CaMKII inhibition ameliorated levodopa-induced dyskinesia by downregulating tyrosine hydroxylase activity in an experimental model of Parkinson's disease.
    Yang X; Zhu Z; Ding X; Wang X; Cui G; Hua F; Xiang J
    Brain Res; 2018 May; 1687():66-73. PubMed ID: 29452071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.
    Morin N; Morissette M; Grégoire L; Di Paolo T
    Curr Neuropharmacol; 2016; 14(5):481-93. PubMed ID: 26639458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C; Crossman AR; Ravenscroft P
    Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits.
    Oh JD; Vaughan CL; Chase TN
    Brain Res; 1999 Mar; 821(2):433-42. PubMed ID: 10064831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism.
    Picconi B; Gardoni F; Centonze D; Mauceri D; Cenci MA; Bernardi G; Calabresi P; Di Luca M
    J Neurosci; 2004 Jun; 24(23):5283-91. PubMed ID: 15190099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in surface expression of N-methyl-D-aspartate receptors in the striatum in a rat model of Parkinson's disease.
    Gan J; Qi C; Mao LM; Liu Z
    Drug Des Devel Ther; 2014; 8():165-73. PubMed ID: 24465126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Striatal overexpression of β-arrestin2 counteracts L-dopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's disease rats.
    Zhang ZR; Zhang XR; Luan XQ; Wang XS; Wang WW; Wang XY; Shao B; Xie CL
    Neurochem Int; 2019 Dec; 131():104543. PubMed ID: 31491493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.
    Fiorentini C; Savoia P; Savoldi D; Barbon A; Missale C
    Neurobiol Dis; 2013 Jun; 54():339-48. PubMed ID: 23328768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat.
    Fiorentini C; Rizzetti MC; Busi C; Bontempi S; Collo G; Spano P; Missale C
    Mol Pharmacol; 2006 Mar; 69(3):805-12. PubMed ID: 16365282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NR2B antagonist CP-101,606 inhibits NR2B phosphorylation at tyrosine-1472 and its interactions with Fyn in levodopa-induced dyskinesia rat model.
    Kong M; Ba M; Liu C; Zhang Y; Zhang H; Qiu H
    Behav Brain Res; 2015 Apr; 282():46-53. PubMed ID: 25576965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NMDA receptor GluN2D subunit participates to levodopa-induced dyskinesia pathophysiology.
    Mellone M; Zianni E; Stanic J; Campanelli F; Marino G; Ghiglieri V; Longhi A; Thiolat ML; Li Q; Calabresi P; Bezard E; Picconi B; Di Luca M; Gardoni F
    Neurobiol Dis; 2019 Jan; 121():338-349. PubMed ID: 30261285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AMPA receptor antagonist LY293558 reverses preproenkephalin mRNA overexpression in the striatum of 6-OHDA-lesioned-rats treated with L-dopa.
    Périer C; Marin C; Bonastre M; Tolosa E; Hirsch EC
    Eur J Neurosci; 2002 Dec; 16(11):2236-40. PubMed ID: 12473092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the D1-N-methyl-D-aspartate receptor complex reduces L-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's rats.
    Song L; Zhang Z; Hu R; Cheng J; Li L; Fan Q; Wu N; Gan J; Zhou M; Liu Z
    Drug Des Devel Ther; 2016; 10():547-55. PubMed ID: 26893543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
    Tronci E; Fidalgo C; Zianni E; Collu M; Stancampiano R; Morelli M; Gardoni F; Carta M
    Neuroscience; 2014 Apr; 265():245-52. PubMed ID: 24486947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterizing the differential roles of striatal 5-HT
    Meadows SM; Chambers NE; Conti MM; Bossert SC; Tasber C; Sheena E; Varney M; Newman-Tancredi A; Bishop C
    Exp Neurol; 2017 Jun; 292():168-178. PubMed ID: 28342749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia.
    Errico F; Bonito-Oliva A; Bagetta V; Vitucci D; Romano R; Zianni E; Napolitano F; Marinucci S; Di Luca M; Calabresi P; Fisone G; Carta M; Picconi B; Gardoni F; Usiello A
    Exp Neurol; 2011 Dec; 232(2):240-50. PubMed ID: 21946266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.